Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Terminated × rrCLL × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 278 Carcinoma, Non-Small-Cell Lung 246 Leukemia, Myeloid, Acute 189 Breast Neoplasms 150 Melanoma 147 Neoplasm Metastasis 146 Multiple Myeloma 124 Recurrence 120 Colorectal Neoplasms 117 Lymphoma, Non-Hodgkin 112 Lymphoma 112 Leukemia, Lymphocytic, Chronic, B-Cell 107 Ovarian Neoplasms 99 Pancreatic Neoplasms 98 Precursor Cell Lymphoblastic Leukemia-Lymphoma 91 Leukemia 85 Prostatic Neoplasms 83 Lung Neoplasms 78 Lymphoma, Large B-Cell, Diffuse 75 Squamous Cell Carcinoma of Head and Neck 73 Glioblastoma 72 Carcinoma, Renal Cell 72 Myelodysplastic Syndromes 67 Lymphoma, Follicular 65 Brain Neoplasms 59 Lymphoma, Mantle-Cell 55 Stomach Neoplasms 52 Sarcoma 52 Head and Neck Neoplasms 51 Triple Negative Breast Neoplasms 49

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡